Choi Sang Il, Seo Ki Woo, Kook Myeong Cherl, Kim Chan Gyoo, Kim Young Woo, Cho Soo Jeong
National Cancer Center, Center for Gastric Cancer, Goyang, Korea.
Turk J Gastroenterol. 2017 May;28(3):166-170. doi: 10.5152/tjg.2017.16346.
BACKGROUND/AIMS: Galectin-9 (Gal-9) is a member of the β-galactoside-binding lectin family. Our previous study revealed that Gal-9 suppresses migration, invasion, and epithelial-mesenchymal transition in gastric cancer cells. Gal-9 was reported to have anti-metastatic activity in patients with malignant melanoma, breast cancer, and hepatocellular carcinoma. Therefore, we aimed to evaluate the prognostic significance of Gal-9 in patients with gastric cancer.
The clinical significance of Gal-9 was explored using clinical and pathological data from 619 patients with gastric cancer who underwent gastrectomy at National Cancer Center, Korea. Tissue microarray and immunohistochemical analyses were used to evaluate Gal-9 expression. The median follow-up duration was 65.7 months (range 0-79 months). Kaplan-Meier method was used to evaluate survival. Log-rank test was used to assess the differences in survival.
Based on the tumoral expression of Gal-9, 619 patients with gastric cancer were classified into two groups: Gal-9-positive patients (327, 52.8%) and Gal-9-negative patients (292, 47.2%). The Gal-9-positive group had a significantly lower overall (p=0.001, by log-rank test) and gastric cancer-specific mortalities (p<0.001) compared to the Gal-9-negative group. In multivariate analysis, which included the depth of invasion and lymph-node metastasis, Gal-9 positivity showed a trend toward improved prognosis but did not reach statistical significance (hazard ratio, 0.8; 95% confidence interval, 0.55-1.31).
Tumoral expression of Gal-9 may suppress tumor progression in patients with gastric cancer.
背景/目的：半乳糖凝集素-9（Gal-9）是β-半乳糖苷结合凝集素家族的成员。我们之前的研究表明，Gal-9可抑制胃癌细胞的迁移、侵袭及上皮-间质转化。据报道，Gal-9在恶性黑色素瘤、乳腺癌和肝细胞癌患者中具有抗转移活性。因此，我们旨在评估Gal-9在胃癌患者中的预后意义。
利用韩国国立癌症中心619例行胃切除术的胃癌患者的临床和病理数据，探讨Gal-9的临床意义。采用组织芯片和免疫组化分析评估Gal-9的表达。中位随访时间为65.7个月（范围0 - 79个月）。采用Kaplan-Meier法评估生存率。采用对数秩检验评估生存率的差异。
根据Gal-9的肿瘤表达情况，619例胃癌患者分为两组：Gal-9阳性患者（327例，52.8%）和Gal-9阴性患者（292例，47.2%）。与Gal-9阴性组相比，Gal-9阳性组的总死亡率（对数秩检验，p = 0.001）和胃癌特异性死亡率（p < 0.001）显著更低。在包括浸润深度和淋巴结转移的多因素分析中，Gal-9阳性显示出预后改善的趋势，但未达到统计学意义（风险比，0.8；95%置信区间，0.55 - 1.31）。
Gal-9的肿瘤表达可能抑制胃癌患者的肿瘤进展。
